Gilead Sciences Stock Options Expiring on 24th of January 2025

GILD Stock  USD 92.34  1.75  1.93%   
Gilead Sciences' latest option contracts expiring on 2025-01-24 are carrying combined implied volatility of 0.04 with a put-to-call open interest ratio of 0.0 over 9 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on 2025-01-24. The total put volume is at 31.0, with calls trading at the volume of 31.0. This yields a 0.51 put-to-call volume ratio.
Gilead Sciences' stock options are financial instruments that give investors the right to buy or sell shares of Gilead Sciences common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Gilead stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Gilead Sciences' stock price goes up or down, the stock options follow.
At present, Gilead Sciences' Common Stock Shares Outstanding is projected to increase significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 65.2 B, whereas Capital Stock is forecasted to decline to about 901 K.

Gilead Current Options Market Mood

Gilead Sciences' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Gilead Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Volume

Unfortunately, most Gilead Sciences' options investors are not very successful. Gilead Sciences' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.

Rule 16 of the current Gilead contract

Base on the Rule 16, the options market is currently suggesting that Gilead Sciences will have an average daily up or down price movement of about 0.002331% per day over the life of the 2025-01-24 option contract. With Gilead Sciences trading at USD 92.34, that is roughly USD 0.002153. If you think that the market is fully incorporating Gilead Sciences' daily price movement you should consider buying Gilead Sciences options at the current volatility level of 0.0373%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  

Gilead Sciences Option Chain

When Gilead Sciences' strike price is surpassing the current stock price, the option contract against Gilead Sciences stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Gilead Sciences' option chain is a display of a range of information that helps investors for ways to trade options on Gilead. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Gilead. It also shows strike prices and maturity days for a Gilead Sciences against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntExpirationCurrent SpreadLast Price
Call
GILD Option Call 24-01-2025 9302025-01-240.0 - 0.03.0Out
Call
GILD Option Call 24-01-2025 9502025-01-240.0 - 0.01.65Out
Call
GILD Option Call 24-01-2025 9902025-01-240.0 - 0.00.93Out
Call
GILD Option Call 24-01-2025 10002025-01-240.0 - 0.00.66Out
Call
GILD Option Call 24-01-2025 10302025-01-240.0 - 0.00.33Out
 Put
GILD Option Put 24-01-2025 8202025-01-240.0 - 0.00.51Out
 Put
GILD Option Put 24-01-2025 8602025-01-240.0 - 0.00.71Out
 Put
GILD Option Put 24-01-2025 9302025-01-240.0 - 0.04.67In
 Put
GILD Option Put 24-01-2025 9502025-01-240.0 - 0.04.75In

Gilead Sciences Selling And Marketing Expenses Over Time

   Selling And Marketing Expenses   
       Timeline  

Gilead Total Stockholder Equity

Total Stockholder Equity

23.97 Billion

At present, Gilead Sciences' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting.

Gilead Sciences Corporate Management

Johanna MercierChief Commercial OfficerProfile
Michael QuigleyVP BiologyProfile
Linda HigginsInnovation ResearchProfile
Deborah TelmanGeneral AffairsProfile
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.42)
Dividend Share
3.06
Earnings Share
0.09
Revenue Per Share
22.703
Quarterly Revenue Growth
0.07
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.